<unk>  conjugate vaccines have been shown to be universally effective against all manifestations of<unk>  disease, with a clinical efficacy among fully vaccinated children estimated to be between 95–100%. The vaccine has also been shown to be immunogenic in patients at high risk of invasive disease.<unk>  is not effective against non-type B Haemophilus influenzae. However, non-type B disease is rare in comparison to pre-vaccine rates of Haemophilus influenzae type B disease. Impact Prior to introduction of the conjugate vaccine,<unk>  was a leading cause of childhood meningitis, pneumonia, and epiglottitis in the United States, causing an estimated 20,000 cases a year in the early 1980s, mostly in children under five years old. Since routine vaccination began, the incidence of<unk>  disease has declined by greater than 99%, effectively eliminating<unk>  as a public health problem. Similar reductions in disease occurred after introduction of the vaccine in Western Europe and developing countries. After routine use of the vaccine in the United States from 1980 to 1990, the rate of invasive<unk>  disease decreased from 40–100 per 100,000 children down to fewer than one per 100,000. Recommendations The CDC and the WHO recommend that all infants be vaccinated using a polysaccharide-protein conjugate<unk> , starting after the age of six weeks. The vaccination is also indicated in people without a spleen.
Hib vaccine
Typhus vaccine
MMR vaccine
MMRV vaccine
Measles vaccine
Polio vaccine
DPT vaccine
Typhoid vaccine